IDH2 and central nervous system cancer: Existing clinical data suggest that grade 2 and grade 3 patients may have similar clinical outcomes, as evidenced by Reuss et al., who reported median overall survival times for patients with grade 2 and grade 3 IDH-mutant glioma across three separate clinical cohorts as 10.9 years and 9.3 years, respectively47.